Follistatin, Exercise, and Natural Levels

Follistatin is a naturally occurring glycoprotein (gene symbol FST) that binds and inhibits myostatin and related activin-family signals involved in muscle growth regulation. Follistatin-like 1 (FSTL1) is a separate but structurally related myokine, secreted by skeletal muscle during exercise, that shows up throughout the sports-science literature under similar names. Follistatin-344 is a synthetic, unapproved research compound, a truncated isoform of the native protein, sold as an injectable for off-label muscle-building use. These three things get discussed interchangeably in marketing copy. They are not the same molecule, and evidence about one does not automatically transfer to the others.

The question worth asking is not "how do I raise my follistatin naturally," a framing that assumes a single dial exists. The better question is whether the studies people cite to justify natural follistatin optimization, or to justify injecting Follistatin-344, are even measuring the same biology. Mostly they are not.

Does exercise change circulating follistatin or FSTL1?

Yes, in the sense that multiple controlled studies have detected acute and training-related shifts in serum follistatin or FSTL1.

• Acute eccentric exercise altered circulating and skeletal-muscle myostatin, follistatin, and decorin in a time-dependent way in a rat model (Physiological Research, 2022).
• Resistance exercise increased muscle myostatin mRNA and protein acutely, with corresponding downstream changes in circulating levels alongside decorin, a related extracellular matrix protein (Journal of Sports Science & Medicine, 2022).
• High-intensity interval training and resistance training both affected follistatin and myostatin levels in the gastrocnemius muscle of aged female rats, with modality-specific differences (Biogerontology, 2025).
• Aerobic training in obese rats increased FSTL1 secretion from skeletal muscle, linked to arterial stiffness improvements via nitric oxide pathways, a cardiovascular rather than muscle-mass endpoint (Physiological Reports, 2022).
• FSTL1 also functions as a lipid-mobilizing myokine during endurance exercise and recovery in human research (Obesity, 2024).
• An autoregulated 8-week resistance program produced anabolic myokine responses, including follistatin-family markers, in recreationally active men, compared with a linear program (Hormones, 2024).

The direction and magnitude of these changes vary by exercise mode, species, age, and baseline adiposity. None of these studies report a target serum follistatin level associated with a defined clinical or performance outcome. The changes are real and reproducible in some designs, but they describe a physiological response to training load, not a therapeutic dose-response relationship.

Does weight loss or diet affect follistatin?

There is supporting evidence, mostly in people with obesity or impaired glucose metabolism.

• A study of overweight adults with impaired glucose metabolism examined how increased physical activity and weight-loss diets, alone or combined, affected serum myokine and adipokine levels including follistatin (Journal of Diabetes and Its Complications, 2021).
• Serum follistatin levels were independently associated with exercise tolerance in patients with obesity, suggesting the marker tracks cardiometabolic fitness rather than muscle mass alone (Endocrine Research, 2023).
• The rate of weight loss itself affected myostatin and follistatin dynamics in patients with obesity, with faster loss producing different biomarker trajectories than gradual loss (Frontiers in Endocrinology, 2024).
• Adipose tissue content was linked to changes in serum exercise-induced adipokines in a quasi-experimental design, reinforcing that body composition, not just training, shapes these levels (International Journal of Environmental Research and Public Health, 2022).

Taken together, these studies describe follistatin as a marker that moves with metabolic health, fat mass, and training status in people who already have impaired glucose metabolism or obesity. They were not designed to test whether a healthy, normal-weight adult can "raise" follistatin for muscle-building purposes, and none report that outcome.

Does genetics set a ceiling on this?

Partly. A 2025 study of Northern Han Chinese adults found FST gene polymorphisms associated with musculoskeletal traits, with effects that differed by sex and by exercise modality (Genes, 2025). This is the one study in this evidence set examining the actual FST gene rather than FSTL1, and it points to individual genetic variation shaping how a person's follistatin biology responds to training. It does not identify an actionable lifestyle intervention, and it has not been replicated across other populations.

Can a blood test tell you your follistatin is low?

There is no established clinical reference range for serum follistatin or FSTL1 tied to muscle growth potential, and no professional guideline recommends testing it for that purpose. The studies above used research assays in controlled trial settings, often in people with specific disease states (obesity, hemodialysis, post-cardiac-event rehabilitation). A commercial lab value obtained outside that context has no validated interpretation. Related findings include follistatin and FSTL1 associations with exercise tolerance in hemodialysis patients (Medicina, 2023) and with outcomes in cardiac rehabilitation after acute coronary syndrome (Scientific Reports, 2025), both disease-specific contexts that do not generalize to a healthy person asking "should I get tested."

What this does not tell you about injectable Follistatin-344

None of the human or animal studies cited on this page administered Follistatin-344 as a peptide. They measured how the body's own follistatin or FSTL1 responded to exercise, diet, or disease state. Extrapolating from "exercise raises a myokine in this family" to "therefore an injectable analog of a different follistatin isoform will build muscle safely" is not a supported inference. For what is actually known and unknown about the injectable compound itself, see what Follistatin-344 is and how it's marketed, the myostatin-follistatin mechanism, and the current evidence quality review. Follistatin-344 has no FDA-approved indication and is not on FDA's 503A bulk substances list; regulatory status can be checked on the FDA Peptide Status Tracker.

Evidence boundary

Established: exercise and weight loss change circulating follistatin and FSTL1 in specific trial populations, mostly people with obesity, impaired glucose metabolism, or cardiac/renal disease. Plausible but unproven: genetic variation in the FST gene may shape individual responsiveness to training; whether this has practical relevance for a specific person is not something a single study can answer. Not established: that any lifestyle intervention reliably raises follistatin in healthy adults for the purpose of muscle building, that a commercial follistatin blood test has diagnostic or optimization value, or that findings about endogenous FSTL1/follistatin apply to injected Follistatin-344.

Framework: what each intervention actually measured

The pattern across every row: real biology, narrow population, and no line of evidence that connects back to the injectable product marketed under the same family name. If you are weighing the injectable peptide specifically, the dosing claims review and side effects and risks page address that evidence gap directly, and a comparison against a well-studied, inexpensive option is available on the follistatin vs creatine page.

If you are considering any peptide product for muscle building outside a supervised research setting, talk with a physician first, particularly if you have a cardiac, renal, or endocrine condition, since several of the studies above found follistatin-family markers behave differently in those populations. Seek urgent care for any injection-site infection, chest pain, or unexplained swelling rather than attributing symptoms to a supplement or unregulated peptide.